September 25, 2018Open Access

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by Merck Sharp KEYNOTE-407 ClinicalTrials.gov number, NCT02775435 .).

Read Full Paperexternally

AI에게 질문

Bookmark

View Full Paper

Cite This Study

Paz‐Ares et al. (Tue,) studied this question.

synapsesocial.com/papers/6985ef823b00292770426f40 https://doi.org/https://doi.org/10.1056/nejmoa1810865

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer2018 · 6,620 citations
224-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer2018 · 197 citations
3IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.2018 · 220 citations
4AJCC Cancer Staging Manual2010 · 1,329 citations
5OA 17.06 Updated Analysis of KEYNOTE-024: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC With PD-L1 TPS ≥50%2017 · 70 citations

AI에게 질문

Bookmark

View Full Paper